RecallReported October 28, 2026
Class II recall by Pfizer
Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, M…
FDA's enforcement report of October 28, 2026 lists a Class II recall by Pfizer of Manhattan, NY. Product: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, M…. Status: Ongoing.
On the record
- Recalling firm
- Pfizer
- Location
- Manhattan, NY
- Classification
- Class II
- Status
- Ongoing
- Recall number
- D-0052-2027
- Product type
- Drugs
- Brand names
- LEVOXYL
- Generic names
- LEVOTHYROXINE SODIUM
- Recall initiated
- 2026-09-29
- Reported by FDA
- 2026-10-28
The full record
An account shows the reason for the recall, where the product was distributed and the lots.
What a recall is
FDA classifies a recall by the hazard. Class I: a reasonable probability that the product will cause serious adverse health consequences or death. Class II: the product may cause temporary or medically reversible harm, or the probability of serious harm is remote. Class III: the product is not likely to cause adverse health consequences.
More
Watch Pfizer
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA enforcement reports. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Pfizer.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.